Erlotinib 150mg/day, oral daily Bevacizumab 15mg/kg, intravenous q3w

3 trials

Sponsors

Outpatient Oncology Unit, Kyoto University Hospital, Kyushu University

Conditions

Non-Small Cell Lung CancerRefractory or relapsed non-Squamous, non-small cell lung cancer

Phase 2

Phase II study of Erlotinib Plus Bevacizumab in patients with advanced Non-squamous and Non- Small Cell Lung Cancer not harboring EGFR mutation who failed to prior treatment (TAILORED-2 study)

RecruitingJPRN-UMIN000006459

Kyushu UniversityNon-Small Cell Lung Cancer

Start: 2011-10-01Target: 38Updated: 2026-06-29

Phase II study of Erlotinib Plus Bevacizumab in patients with advanced Non-squamous and Non- Small Cell Lung Cancer harboring EGFR mutation who acquired resistance to prior gefitinib treatment (TAILORED-1 study)

RecruitingJPRN-UMIN000006457

Kyushu UniversityNon-Small Cell Lung Cancer

Start: 2011-10-01Target: 30Updated: 2026-06-29

Unknown Phase

Phase II study of Bevacizumab and Erlotinib in patients with non-Squamous non-small cell lung cancer that is refractory or relapsed after 1-2 previous Treatment

Active, not recruitingJPRN-UMIN000004255

Outpatient Oncology Unit, Kyoto University HospitalRefractory or relapsed non-Squamous, non-small cell lung cancer

Start: 2010-11-01Target: 80Updated: 2026-06-29

Related Papers

Design paper: a phase II study of bevacizumab and erlotinib in patients with non-squamous non-small cell lung cancer that is refractory or relapsed after 1-2 previous treatment (BEST).

2011-05-124 citations